Cyclosporin A (CsA) is used to prevent rejection in transplantation and to treat autoimmune and hematologic diseases such as aplastic anemia. However, the tumor growth-promoting effect of CsA remains controversial. We report the case of a 24-year-old man who developed acute lymphoblastic leukemia of precursor-T-cell origin after 75 months of treatment with CsA for aplastic anemia. The surface antigen phenotype of his leukemic cells was CD2+, CD3+, CD5+, CD7+, CD4−, CD8−, CD10−, CD20−, CD34−, CD41−, and CD56−. Southern blot analysis revealed a monoclonal rearrangement of T-cell receptor—J nongermline fragments inHindIII digestion.
T-ALL Cyclosporin A Aplastic anemia
This is a preview of subscription content, log in to check access.
van den Borne BEEM, Landewe RBM, Houkes I, et al. No increased risk of malignancies and mortality in cyclosporin A-treated patients with rheumatoid arthritis.Arthritis Rheum. 1998;41:1930–1937.CrossRefPubMedPubMedCentralGoogle Scholar
De Planque MM, Bacigalupo A, Wursch A, et al. Long-term follow-up of severe aplastic anemia patients treated with antithymocyte globulin.Brit J Haematol. 1989;73:121–126.CrossRefGoogle Scholar
Tooze JA, Marsh JCW, Gordon-Smith EC. Clonal evolution of aplastic anaemia to myelodysplastic/acute myeloid leukemia and paroxysmal nocturnal haemoglobinuria.Leuk Lymphoma. 1999;33:231–241.CrossRefPubMedPubMedCentralGoogle Scholar
de Planque MM, Kluin-Nelemans HC, van Krieken HJ. Evolution of acquired severe aplastic anaemia to myelodysplasia and subsequent leukaemia in adults.Brit J Haematol. 1988;70:55–62.CrossRefGoogle Scholar
Ohhara A, Kojima S, Hamajim N, et al. Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia.Blood. 1997;90:1009–1013.Google Scholar
Sarangi JN, Kashyap R, Choudhry VP, et al. Severe aplastic anemia evolving into T cell acute lymphoblastic leukemia [letter].Eur J Haematol. 1999;63:269–271.CrossRefPubMedGoogle Scholar
Takeuchi M, Soda R, Takahashi K, et al. Philadelphia chromosome positive acute lymphocytic leukemia arising from aplastic anemia [letter].Am J Hematol. 2000;63:161–162.CrossRefPubMedGoogle Scholar
Welch DR, Farba A, Nakajima M. Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metastatic potential.Proc Natl Acad Sci U S A. 1990;87:7678–7682.CrossRefPubMedPubMedCentralGoogle Scholar
Arrick BA, Lopez AR, Elfman F, Ebner R, Damsky CH, Derynck R. Altered metabolic and adhesive properties and increased tumorigenesis associated with increased expression of transforming growth factor β1.J Cell Biol. 1992;18:715–726.CrossRefGoogle Scholar
Caulin C, Scholl FG, Frontelo P, Gamallo C, Quantanilla M. Chronic exposure of cultured transformed mouse epidermal cells to transforming growth factor-beta1 induces an epithelial-mesenchymal transdifferentiation and a spindle tumoral phenotype.Cell Growth Differ. 1995;6:1027–1035.PubMedGoogle Scholar
Cui W, Fowlis DJ, Bryson S, et al. TGF β1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice.Cell. 1996;86:531–542.CrossRefPubMedPubMedCentralGoogle Scholar